New diabetes pill DA-2811 aims to improve blood sugar control
NCT ID NCT07239440
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug, DA-2811, in 288 adults with type 2 diabetes whose blood sugar is not well controlled despite taking two other diabetes medications. Participants will receive either DA-2811 or a placebo added to their current treatment. The main goal is to see if DA-2811 lowers HbA1c, a key blood sugar measure, over the study period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DA-2811 (an experimental oral drug for diabetes)
- What this could lead to
- If successful, this could provide a new add-on treatment option to help people with type 2 diabetes better manage their blood sugar levels.
- What could go wrong
- This is an early Phase 2 trial, so the drug may not prove effective or safe. It is only tested in a specific group and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections